Elranatamab + Radiotherapy for Multiple Myeloma

This trial aims to determine if a low dose of radiation can enhance the effectiveness of elranatamab, a new potential drug, in killing cancer cells in people with multiple myeloma, a type of blood cancer. It targets individuals whose cancer has returned or did not respond well to previous treatments. Ideal candidates have multiple myeloma that worsened after stopping treatment and have visible tumors outside the bones that can be targeted with radiation. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop taking certain medications before starting the study. Specifically, you must not have taken investigational treatments within 14 days or 5 half-lives, whichever is less, and must stop IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies at least 7 days before the first dose of the study drug.

Research has shown that elranatamab is generally safe for people. Patients with relapsed or refractory multiple myeloma (RRMM) who used it did not encounter new safety issues compared to other treatments targeting the BCMA protein on cancer cells. Studies have found that even those with more severe disease had a safe experience with elranatamab. While all treatments carry risks, elranatamab has proven safe for many patients in previous trials.¹²³⁴

Unlike the standard treatments for multiple myeloma, which often involve combinations of chemotherapy, steroids, and immunomodulatory drugs, Elranatamab works by targeting a specific protein called BCMA on the surface of myeloma cells. This targeted approach allows it to engage the immune system more directly and efficiently, potentially leading to better outcomes. Researchers are particularly excited about Elranatamab because it is administered as a subcutaneous injection, which can be more convenient and less invasive than traditional intravenous treatments. Additionally, the combination of Elranatamab with radiotherapy is believed to enhance the immune system's response, offering a novel strategy that could improve the overall response rate compared to existing therapies.

Research has shown that elranatamab, which participants in this trial will receive, may effectively treat multiple myeloma, a type of blood cancer. One study found that 71% of patients treated with elranatamab saw their cancer improve. Another study reported a 65% improvement rate, with some patients experiencing significant or complete reduction of their cancer. When combined with another drug, elranatamab increased the improvement rate to 95.5% in certain patients. These findings suggest that elranatamab effectively fights multiple myeloma.⁵⁶⁷⁸